HYPERACUSIS AND TINNITUS
The ØREBLUE® method is a personalized sound-based hearing therapy designed
to restore cortical organization.
Its aim is to reduce hyperactive nervous system responses (in the autonomic and limbic systems)
in the case of tinnitus, and to increase the dynamic range of sound by increasing the plasticity
of subconscious neural networks stimulated in the case of hyperacusis.
It has been observed that the symptoms of tinnitus and hyperacusis provoke generalized
states of hypervigilance in subjects, which lead to an aversive reflex, similar to the reflex that is triggered
by any threat to well-being.
In such cases, the brain may attempt to filter or remove the subject from the stimulus identified as intrusive.
This is why, unlike therapies that use noise generators, the ØREBLUE® method uses music.
One of the major advantages of this choice is to place the patient in a highly receptive state,
which increases the acceptability of the treatment.
This audible tool is modified using a software program whose specially-developed algorithms
apply acoustic filters tailored to the patient’s medical and emotional hearing pattern,
which means that each therapeutic program is both precise and fully personalized.
The ØREBLUE® method was developed thanks to the large volume of medical and acoustic
data analyzed, and thanks to the development by a French engineering firm of an innovative
digital device to process sound signals.
The ØREBLUE® method now makes it possible to permanently eliminate the symptoms
of hyperacusis and to significantly reduce, or even eliminate, the symptoms of tinnitus,
rather than artificially blocking them out.
Certified Medical Devices
Agence Nationale de Sécurité du Médicament et des Produits de Santé
The device developed for the ØREBLUE® method is certified as officially meeting the highest safety and performance standards required for healthcare equipment, and guarantees that the risk-benefit ratio has been clearly demonstrated in treatments of hyperacusis and tinnitus, in accordance with EU Directive 93/42/EEC on medical devices.